SRTOY - Sartorius Stedim Biotech S.A. Non-GAAP EPS of Euro2.21 revenue of Euro862.5M

Sartorius Stedim Biotech S.A. press release (OTCPK:SRTOY): Q1 Non-GAAP EPS of €2.21. Revenue of €862.5M (+31.6% Y/Y). Underlying EBITDA margin 35.2%. Order intake was in line with expectations compared with the exceptionally strong prior-year quarter, reaching €950M (- 8.6% in constant currencies; reported: - 5.5%). Outlook for 2022 confirmed: Sales revenue expected to rise by 15 to 19 percent (vs. estimated growth of 17.89% Y/Y), with non-organic growth from acquisitions projected to contribute about 2 percentage points and underlying EBITDA margin projected to be more than 35 percent. The CAPEX ratio is anticipated to be about 14.5 percent and net debt to underlying EBITDA to be about 0.2 at year-end.

For further details see:

Sartorius Stedim Biotech S.A. Non-GAAP EPS of €2.21, revenue of €862.5M